{
}
Gilead Sciences has received several price target increases from analysts, with Oppenheimer and JPMorgan raising their targets to $105, while BMO Capital Markets set theirs at $102. Despite a "Moderate Buy" rating, top analysts favor five other stocks over Gilead. Insider trading activity shows significant sales, with insiders offloading over 63,000 shares in the past ninety days.
Johanna Mercier
People
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
gilead sciences receives mixed analyst ratings and insider selling raises concerns
14:22 28.11.2024
Trending
Subcategory
Industry Trends
Corporate News
Startups & Entrepreneurship
Global Trade Developments
Retail and Consumer Goods
Stock Market Updates
Supply Chain Management
Government Economic Policies
Fintech Startups
Industry Mergers & Acquisitions
Private Equity Deals
Venture Capital Investments
CEO Changes
AI Applications
Funding Rounds & Investments
Economic Indicators
Emerging Startups
Corporate Social Responsibility
Inflation and Monetary Impact
Finance Mergers & Acquisitions
Countries:
Companies:
Apple Inc.
Grab2Go AS
Google Inc.
OLA ELECTRIC MOBILITY LTD
NVIDIA Corp
Amazon.com, Inc.
Microsoft Corporation
EFG Hermes Egypt
Broadcom Inc.
The Goldman Sachs Group, Inc.
JPMorgan Chase & Co.
XIAOMI-W
Tesla, Inc.
LG CNS
Delhivery Limited
Ecom Express Ltd.
Scripbox.COM India Ltd.
SK hynix Inc.
Tesmec S.p.A.
OpenAI ERC USD
Currencies:
United States Dollar
Indian Rupee
Chinese Yuan
Japanese Yen
Euro
United Arab Emirates Dirham
South Korean Won
Pakistani Rupee
Egyptian Pound
Saudi Riyal
Brazilian Real
Qatari Riyal
Indonesian Rupiah
Vietnamese Đồng
Hong Kong Dollar
Offshore Chinese Yuan
Canadian Dollar
Malaysian Ringgit
Swiss Franc
New Zealand Dollar
People: